close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

208.91 +0.46 (+0.22%)
Streaming Delayed Price Updated: 11:53 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call
Biogen’s second quarter witnessed a positive market response, buoyed by notable revenue growth and a significant beat on non-GAAP profit relative to analysts... 
Via StockStory
Topics Earnings
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
It's effecting a "merger of equals" with a peer. 
Via The Motley Fool
News headline image
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion... 
Via StockStory
News headline image
Why Biogen Stock Topped the Market Today ↗
The company published its second-quarter results on Wednesday morning. 
Via The Motley Fool
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Biogen Q2 Earnings Call Highlights ↗
Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results.... 
Via MarketBeat
Topics Earnings
News headline image
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP prof... 
Via StockStory
News headline image
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for. Biogen beat analysts’ revenue exp... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Profitable Stocks We Steer Clear Of
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Biogen Appoints Michael J. Parini as Chief Legal Officer
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to... 
Via StockStory
Topics Stocks
Discover which S&P500 stocks are making waves on Tuesday. ↗
Via Chartmill
News headline image
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss ↗
Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary... 
Via MarketBeat
These S&P500 stocks are moving in today's session ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
1 Mid-Cap Stock to Target This Week and 2 We Find Risky
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
Stock Market Today, July 13: Energy Stocks Cushion Dow as Tech Slides on Geopolitical Tensions ↗
Energy names help cushion the Dow as oil jumps on U.S.–Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026. 
Via The Motley Fool
Topics Economy Stocks
News headline image
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool
News headline image
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors. ↗
This could be a key move for future growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock with Promising Prospects and 2 We Question
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Energy Stocks
News headline image
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
From Block & Leviton LLP
Via GlobeNewswire
News headline image
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
From Biogen Inc.
Via GlobeNewswire
News headline image
Why Biogen (BIIB) Stock Is Up Today
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth sign... 
Via StockStory
Topics Artificial Intelligence Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
From Pomerantz LLP
Via GlobeNewswire
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next ... 
Via StockStory
Topics Artificial Intelligence
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.